Lilly 2005 Sales Growth Will Rest On Strength Of New Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.